We are committed to bringing innovative treatments to patients suffering from rare CNS diseases.

Clinical Trials are necessary to evaluate the efficacy and safety of the new treatments in humans. To overcome the many challenges arising when conducting Clinical Trials, we strongly believe in the involvement of volunteers, patients and patient families.


Safety and tolerability of CTH120, first-in-human phase I study encompassing three parts: Single and Multiple Ascending doses and potential Food Interaction

CONNECTA’s first in class small molecule, CTH120, developed for the potential treatment of Fragile X Syndrome (FXS) and other neurodevelopmental disorders, is an Investigational Medicinal Product (IMP) currently undergoing its First in Human (FIH) clinical trial. 

This clinical trial is divided in three parts: FIH-CTH120-SAD (Single Ascending Doses), FIH-CTH120-MAD (Multiple Ascending Doses) and FIH-CTH120-FI (Food Interaction) in healthy volunteers, and is being conducted at the Hospital del Mar Research Institute in Barcelona.

Learn more about this clinical trial at:

Recruitment Page (Spanish Version)

Recruitment Page (Catalan Version)


For more information about the study please contact +34 93.316.04.96 or send an email to